MiMedx(MDXG) - 2025 Q2 - Quarterly Results

Filing Information This section provides essential company identification, contact details, and securities information for MiMedx Group, Inc Registrant Details This section provides the essential identification and contact information for MiMedx Group, Inc., the registrant of this Form 8-K - Registrant: MIMEDX GROUP, INC.[1] - Jurisdiction of incorporation: Florida[1] - Principal executive offices address: 1775 West Oak Commons Ct., NE, Marietta GA 30062[1] - Telephone number: (770) 651-9100[1] Securities and Company Status This section details the company's registered securities and confirms its status regarding emerging growth company provisions Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.001 par value per share | MDXG | The Nasdaq Stock Market LLC | - The registrant is not an emerging growth company[3] Cautionary Statements This section outlines the company's forward-looking statements and the various risk factors that could impact future results Forward-Looking Statements This section highlights the inclusion of forward-looking statements within the report, covering future financial performance, market expectations, and growth, and identifies the terminology used to recognize such statements - Forward-looking statements include expectations regarding future sales or sales growth, 2025 and longer-term financial goals (net sales, Adjusted EBITDA, Adjusted EBITDA margin, corporate expenses, cash), the placental tissue market, Medicare spending reform, and continued growth in different care settings[4] - Such statements are identified by words like "believe," "expect," "may," "plan," "goal," "outlook," "potential," "will," "preliminary," and similar expressions[4] Risk Factors This section outlines the various risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, emphasizing factors such as market competition, research outcomes, international market challenges, and regulatory changes - Factors that could cause actual results to differ include: future sales uncertainties (competition, customer access, reimbursement), unforeseen changes in company plans, uncertain value of scientific research, challenges in selling products internationally (reimbursement, market acceptance, sales force), ongoing studies on amniotic tissue effectiveness, potential alterations in R&D expenditures based on regulatory developments, Medicare spending, and changes in the addressable market size[5] - Additional risks and uncertainties are described in the Risk Factors section of the Company's most recent annual and quarterly reports filed with the SEC[5] Current Report Items This section details the company's financial results announcement, investor communication plans, and accompanying exhibits for the current report Item 2.02 Results of Operations and Financial Condition MiMedx Group, Inc. announced its financial results for the quarter ended June 30, 2025, through an Earnings Press Release issued on July 30, 2025, which is attached as Exhibit 99.1 and incorporated by reference - On July 30, 2025, MiMedx Group, Inc. issued an Earnings Press Release announcing its results for the quarter ended June 30, 2025[6] - The Earnings Press Release (Exhibit 99.1) is attached and incorporated by reference[6] - The information is furnished, not "filed," under Section 18 of the Securities Exchange Act of 1934[7] Item 7.01 Regulation FD Disclosure The company disclosed its plan to host an earnings conference call and webcast on July 30, 2025, and furnished the related slide presentation and investor presentation materials as Exhibits 99.2 and 99.3, respectively - MiMedx Group, Inc. intends to host an Earnings Call and webcast on July 30, 2025, at 4:30 PM Eastern Daylight Time, to discuss its financial and operating results[8] - A slide presentation for the Earnings Call (Exhibit 99.2) and investor presentation materials (Exhibit 99.3) are attached and incorporated by reference[8] - The information is furnished, not "filed," under Section 18 of the Securities Exchange Act of 1934[9] Item 9.01 Financial Statements and Exhibits This section lists all exhibits accompanying this Form 8-K filing, including the Earnings Press Release, Earnings Call Presentation, Investor Presentation, and the Inline XBRL formatted cover page Exhibits Filed with Form 8-K | Exhibit No. | Description of Exhibit | | :---------- | :------------------------------------- | | 99.1 | Earnings Press Release dated July 30, 2025 | | 99.2 | Earnings Call Presentation dated July 30, 2025 | | 99.3 | Investor Presentation dated August 2025 | | 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. | Signatures This section confirms the official signing of the report by the authorized corporate officer Authorized Signature This section confirms that the report was duly signed on behalf of MiMedx Group, Inc. by its Chief Financial Officer, Doug Rice, on July 30, 2025, in accordance with the requirements of the Exchange Act - The report was signed on behalf of MIMEDX GROUP, INC. by Doug Rice, Chief Financial Officer[13][14] - Date of signature: July 30, 2025[14]